Quick Answer
Rani Therapeutics Holdings, Inc. reported Net Income Loss of -$29.67 million for the year ending 2025.
- Rani Therapeutics Holdings, Inc. showed an increase of +1.1% in Net Income Loss from 2024 to 2025.
- This data is from Rani Therapeutics Holdings, Inc.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: -$5.35 million | Q2 2020: -$2.71 million | Q3 2020: -$2.88 million | Q1 2021: -$5.60 million | Q2 2021: -$5.49 million | Q3 2021: -$3.14 million | Q1 2022: -$6.22 million | Q2 2022: -$7.62 million | Q3 2022: -$7.96 million | Q1 2023: -$8.37 million | Q2 2023: -$9.30 million | Q3 2023: -$9.20 million | Q1 2024: -$7.48 million | Q2 2024: -$6.81 million | Q3 2024: -$6.78 million | Q1 2025: -$7.26 million | Q2 2025: -$6.69 million | Q3 2025: -$5.41 million.
- Over the full 5 years of available data (2021 to 2025), Rani Therapeutics Holdings, Inc.'s Net Income Loss has declined by 256.2%.
- Historical annual values: Fiscal year 2025: -$29.67 million | Fiscal year 2024: -$30.02 million | Fiscal year 2023: -$33.97 million | Fiscal year 2022: -$30.59 million | Fiscal year 2021: -$8.33 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: